SIGA Technologies (NASDAQ:SIGA) Cut to C at TheStreet

SIGA Technologies (NASDAQ:SIGA) was downgraded by investment analysts at TheStreet from an “a-” rating to a “c” rating in a note issued to investors on Tuesday, TheStreetRatingsTable reports.

Separately, Zacks Investment Research upgraded shares of SIGA Technologies from a “hold” rating to a “buy” rating and set a $10.00 price objective on the stock in a research note on Thursday.

NASDAQ:SIGA opened at $8.87 on Tuesday. SIGA Technologies has a fifty-two week low of $5.66 and a fifty-two week high of $9.82. The stock has a market capitalization of $657.41 million, a P/E ratio of 44.35 and a beta of 0.47. The company has a 50 day moving average price of $7.41 and a 200 day moving average price of $6.79.

Large investors have recently bought and sold shares of the company. Advisory Services Network LLC acquired a new stake in shares of SIGA Technologies in the second quarter worth $25,000. FinTrust Capital Advisors LLC purchased a new position in shares of SIGA Technologies in the second quarter valued at $31,000. Royal Bank of Canada boosted its stake in shares of SIGA Technologies by 188.3% in the first quarter. Royal Bank of Canada now owns 5,765 shares of the company’s stock valued at $37,000 after purchasing an additional 3,765 shares during the period. Citigroup Inc. boosted its stake in shares of SIGA Technologies by 59.1% in the second quarter. Citigroup Inc. now owns 8,724 shares of the company’s stock valued at $55,000 after purchasing an additional 3,242 shares during the period. Finally, UBS Group AG boosted its stake in shares of SIGA Technologies by 160.1% in the first quarter. UBS Group AG now owns 9,134 shares of the company’s stock valued at $59,000 after purchasing an additional 5,622 shares during the period. 63.61% of the stock is owned by institutional investors and hedge funds.

About SIGA Technologies

SIGA Technologies, Inc is a commercial-stage pharmaceutical company which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses.

Featured Story: What is Call Option Volume?

Receive News & Ratings for SIGA Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies and related companies with MarketBeat.com's FREE daily email newsletter.